Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Cash: 2015-2024

Historic Change in Cash for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $77.2 million.

  • UroGen Pharma's Change in Cash rose 97.26% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year decrease of 689.79%. This contributed to the annual value of $77.2 million for FY2024, which is 95.04% up from last year.
  • Per UroGen Pharma's latest filing, its Change in Cash stood at $77.2 million for FY2024, which was up 95.04% from $39.6 million recorded in FY2023.
  • UroGen Pharma's 5-year Change in Cash high stood at $77.2 million for FY2024, and its period low was -$8.5 million during FY2021.
  • Its 3-year average for Change in Cash is $42.5 million, with a median of $39.6 million in 2023.
  • Per our database at Business Quant, UroGen Pharma's Change in Cash slumped by 319.23% in 2021 and then skyrocketed by 272.37% in 2023.
  • UroGen Pharma's Change in Cash (Yearly) stood at $3.9 million in 2020, then plummeted by 319.23% to -$8.5 million in 2021, then spiked by 225.06% to $10.6 million in 2022, then surged by 272.37% to $39.6 million in 2023, then soared by 95.04% to $77.2 million in 2024.